Shots:

• The P-III THEMIS study involves assessing of Brilinta (ticagrelor) + aspirin vs aspirin monothx in patients with coronary artery disease (CAD) and type-2 diabetes (T2D) with no prior myocardial infarction or stroke
• The P-III study resulted in meeting its 1EPs with the reduction in the composite of major adverse cardiovascular events (MACE) compared to aspirin alon
• Brilinta (ticagrelor) is an oral P2Y12 receptor antagonist inhibits platelet activation- when administered in combination with aspirin prevents atherothrombotic events in adults with ACS

Ref: AstraZeneca | Image: AstraZeneca